Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin Lymphoma
NCT05201248Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Mar 2022
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in B-cell non-Hodgkin lymphoma, sponsored by Genmab. Started Mar 2022; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05201248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201248.